The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Open accessAbstract
The β-haemoglobinopathies, such as sickle cell disease and β-thalassaemia, are caused by mutations in the β-globin (HBB) gene and affect millions of people worldwide. Ex vivo gene correction in patient-derived haematopoietic stem cells followed by autologous transplantation could be used to cure β-haemoglobinopathies. Here we present a CRISPR/Cas9 gene-editing system that combines Cas9 ribonucleoproteins and adeno-associated viral vector delivery of a homologous donor to achieve homologous recombination at the HBB gene in haematopoietic stem cells. Notably, we devise an enrichment model to purify a population of haematopoietic stem and progenitor cells with more than 90% targeted integration. We also show efficient correction of the Glu6Val mutation responsible for sickle cell disease by using patient-derived stem and progenitor cells that, after differentiation into erythrocytes, express adult β-globin (HbA) messenger RNA, which confirms intact transcriptional regulation of edited HBB alleles. Collectively, these preclinical studies outline a CRISPR-based methodology for targeting haematopoietic stem cells by homologous recombination at the HBB locus to advance the development of next-generation therapies for β-haemoglobinopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, several reports have shown efficient Glu6Val correction in SCD-HSPCs, although correction efficiency can sometimes be linked with off-target INDELs in the same edited population15,16,45,46.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“RNP delivery results in an initially high level of the genome editing machinery followed by rapid decay, leading to a “fast on, fast off” strategy that results in highly efficient editing while minimizing OTEs13–19.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AAV6 homologous donor DNA templates are an efficient way to deliver donor templates for sensitive primary immune cells, including HSPCs and T-Cells15,35–40.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies have shown that disease-causing genetic errors can be corrected using CRISPR/Cas9 in long-term engrafting HSPCs that are preserved in downstream effector lineages15,16,24,25.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Major progress in delivering to 44 and handling HPSCs has resulted in formidable efficiencies of mutation correction or mitigation 18,45-47 that are expected to be curative.”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [45]
Experimental — accuracy not yet measured
In the citing paper
“Furthermore, CRISPR/Cas9 system holds tremendous promise for gene therapy [46–51]. It can correct causal mutations in the original genome and rescue the disease phenotypes of monogenic disorders permanently, which currently represents the most translatable field in CRISPR/Cas9-mediated disease therapy.”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Easy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Gene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-Leukemia
Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, M., Rossini, S., Mavilio, F., Traversari, C., et al. (1997) · Science · doi:10.1126/science.276.5319.1719 · Cited by 1,158
Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells
Hendel, A., Bak, R. O., Clark, J. T., Kennedy, A. B., Ryan, D. E., Roy, S., Steinfeld, I., Lunstad, B. D., Kaiser, R. J., Wilkens, A. B., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3290 · Cited by 1,090
Self-citationIsolation of a candidate human hematopoietic stem-cell population.
Baum, C. M., Weissman, I. L., Tsukamoto, A. S., Buckle, A., & Péault, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2804 · Cited by 1,084
Hematopoietic stem cell: self‐renewal versus differentiation
Seita, J., & Weissman, I. L. (2010) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.86 · Cited by 997
Flagged first, then by citations
Cited by
Sorted by citations
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,829
Kato, G. J., Piel, F. B., Reid, C. D., Gaston, M. H., Ohene-Frempong, K., Krishnamurti, L., Smith, W. R., Panepinto, J. A., Weatherall, D. J., Costa, F. F., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.10 · Cited by 1,501
CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
The promise and challenge of therapeutic genome editing
Doudna, J. A. (2020) · Nature · doi:10.1038/s41586-020-1978-5 · Cited by 1,126
Identification of preexisting adaptive immunity to Cas9 proteins in humans
Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., Vakulskas, C. A., Collingwood, M. A., Zhang, L., Bode, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0326-x · Cited by 1,093
Self-citationReprogramming human T cell function and specificity with non-viral genome targeting
Roth, T. L., Puig-Saus, C., Yu, R., Shifrut, E., Carnevale, J., Li, P. J., Hiatt, J., Saco, J., Krystofinski, P., Li, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0326-5 · Cited by 839
Vakulskas, C. A., Dever, D. P., Rettig, G. R., Turk, R., Jacobi, A. M., Collingwood, M. A., Bode, N. M., McNeill, M. S., Yan, S., Camarena, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0137-0 · Cited by 782
Self-citationLee, K., Conboy, M., Park, H. M., Jiang, F., Kim, H. J., Dewitt, M. A., Mackley, V. A., Chang, K., Rao, A., Skinner, C., et al. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0137-2 · Cited by 755
Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts
Stewart, M. P., Langer, R., & Jensen, K. F. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00678 · Cited by 767
Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J.-A., Hongeng, S., Magrin, E., Schiller, G. J., Payen, E., Semeraro, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705342 · Cited by 684
Paediatric genomics: diagnosing rare disease in children
Wright, C. F., FitzPatrick, D. R., & Firth, H. V. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.116 · Cited by 654
Chromothripsis as an on-target consequence of CRISPR–Cas9 genome editing
Leibowitz, M. L., Papathanasiou, S., Doerfler, P. A., Blaine, L. J., Sun, L., Yao, Y., Zhang, C.-Z., Weiss, M. J., & Pellman, D. (2021) · Nature Genetics · doi:10.1038/s41588-021-00838-7 · Cited by 583
Directed evolution of CRISPR-Cas9 to increase its specificity
Lee, J. K., Jeong, E., Lee, J., Jung, M., Shin, E., Kim, Y.-H., Lee, K., Jung, I., Kim, D., Kim, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05477-x · Cited by 525
Highly efficient therapeutic gene editing of human hematopoietic stem cells
Wu, Y., Zeng, J., Roscoe, B. P., Liu, P., Yao, Q., Lazzarotto, C. R., Clement, K., Cole, M. A., Luk, K., Baricordi, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0401-y · Cited by 515
CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia
Xu, L., Wang, J., Liu, Y., Xie, L., Su, B., Mou, D., Wang, L., Liu, T., Wang, X., Zhang, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817426 · Cited by 454
Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing
Zhang, S., Shen, J., Li, D., & Cheng, Y. (2021) · Theranostics · doi:10.7150/thno.47007 · Cited by 430
Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities
Li, L., Hu, S., & Chen, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.031 · Cited by 415
Xu, Y., & Li, Z. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.08.031 · Cited by 457
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Yu, A., Choi, Y. H., & Tu, M. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019554 · Cited by 421
Base editing of haematopoietic stem cells rescues sickle cell disease in mice
Newby, G. A., Yen, J. S., Woodard, K. J., Mayuranathan, T., Lazzarotto, C. R., Li, Y., Sheppard, H., Porter, S. N., Yao, Y., Mayberry, K. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03609-w · Cited by 402
Schiroli, G., Conti, A., Ferrari, S., della Volpe, L., Jacob, A., Albano, L., Beretta, S., Calabria, A., Vavassori, V., Gasparini, P., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.02.019 · Cited by 342
CRISPR/Cas9 genome editing in human hematopoietic stem cells.
Bak, R. O., Dever, D. P., & Porteus, M. H. (2018) · Nature Protocols · doi:10.1038/nprot.2017.143 · Cited by 319
Self-citationRecent Advances in CRISPR/Cas9 Delivery Strategies
Yip, B. (2020) · Biomolecules · doi:10.3390/biom10060839 · Cited by 292
The delivery challenge: fulfilling the promise of therapeutic genome editing
van Haasteren, J., Li, J., Scheideler, O. J., Murthy, N., & Schaffer, D. V. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0565-5 · Cited by 285
Therapeutic base editing of human hematopoietic stem cells
Zeng, J., Wu, Y., Ren, C., Bonanno, J., Shen, A. H., Shea, D. N., Gehrke, J. M., Clement, K., Luk, K., Yao, Q., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0790-y · Cited by 281
Improving CRISPR-Cas specificity with chemical modifications in single-guide RNAs
Ryan, D. E., Taussig, D., Steinfeld, I., Phadnis, S. M., Lunstad, B. D., Singh, M., Vuong, X., Okochi, K. D., McCaffrey, R., Olesiak, M., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1199 · Cited by 280
Resident and Monocyte-Derived Macrophages in Cardiovascular Disease
Honold, L., & Nahrendorf, M. (2018) · Circulation Research · doi:10.1161/circresaha.117.311071 · Cited by 283
Nidhi, S., Anand, U., Olekšák, P., Tripathi, P., Lal, J. A., Thomas, G., Kuča, K., & Tripathi, V. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073327 · Cited by 310
A Review on Electroporation-Based Intracellular Delivery
Shi, J., Ma, Y., Zhu, J., Chen, Y., Sun, Y., Yao, Y., Yang, Z., & Xie, J. (2018) · Molecules · doi:10.3390/molecules23113044 · Cited by 279
Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9
Gundry, M. C., Brunetti, L., Lin, A., Mayle, A. E., Kitano, A., Wagner, D., Hsu, J. I., Hoegenauer, K. A., Rooney, C. M., Goodell, M. A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.092 · Cited by 265
Capsid modifications for targeting and improving the efficacy of AAV vectors
Büning, H., & Srivastava, A. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.01.008 · Cited by 260
Myeloid cell contributions to cardiovascular health and disease
Nahrendorf, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0064-0 · Cited by 267
Gene therapy using haematopoietic stem and progenitor cells
Ferrari, G., Thrasher, A. J., & Aiuti, A. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-00298-5 · Cited by 263
Refining strategies to translate genome editing to the clinic
Cornu, T. I., Mussolino, C., & Cathomen, T. (2017) · Nature Medicine · doi:10.1038/nm.4313 · Cited by 252
Xu, L., Yang, H., Gao, Y., Chen, Z., Xie, L., Liu, Y., Liu, Y., Wang, X., Li, H., Lai, W., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.027 · Cited by 255
Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned
Morgan, R. A., Gray, D., Lomova, A., & Kohn, D. B. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.10.010 · Cited by 252
He, Q., Yu, D., Bao, M., Korensky, G., Chen, J., Shin, M., Kim, J., Park, M., Qin, P., & Du, K. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112068 · Cited by 240
Methods and Applications of CRISPR-Mediated Base Editing in Eukaryotic Genomes
Hess, G. T., Tycko, J., Yao, D., & Bassik, M. C. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.09.029 · Cited by 234
Mogensen, T. H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03047 · Cited by 235
A New Class of Medicines through DNA Editing
Porteus, M. H. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1800729 · Cited by 229
Self-citationFunctional Genetic Variants Revealed by Massively Parallel Precise Genome Editing
Sharon, E., Chen, S.-A. A., Khosla, N. M., Smith, J. D., Pritchard, J. K., & Fraser, H. B. (2018) · Cell · doi:10.1016/j.cell.2018.08.057 · Cited by 225
CRISPR RNAs Trigger Innate Immune Responses in Human Cells
Kim, S., Koo, T., Jee, H.-G., Cho, H.-Y., Lee, G., Lim, D.-G., Shin, H. S., & Kim, J.-S. (2018) · Genome Research · doi:10.1101/gr.231936.117 · Cited by 222
Correction of β-thalassemia mutant by base editor in human embryos
Liang, P., Ding, C., Sun, H., Xie, X., Xu, Y., Zhang, X., Sun, Y., Xiong, Y., Ma, W., Liu, Y., et al. (2017) · Protein & Cell · doi:10.1007/s13238-017-0475-6 · Cited by 217
Nishiyama, J., Mikuni, T., & Yasuda, R. (2017) · Neuron · doi:10.1016/j.neuron.2017.10.004 · Cited by 215
Schiroli, G., Ferrari, S., Conway, A., Jacob, A., Capo, V., Albano, L., Plati, T., Castiello, M. C., Sanvito, F., Gennery, A. R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0820 · Cited by 214
Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells
Tsuchida, C. A., Brandes, N., Bueno, R., Trinidad, M. I., Mazumder, T., Yu, B., Hwang, B., Chang, C. R., Liu, J., Sun, Y., et al. (2023) · Cell · doi:10.1016/j.cell.2023.08.041 · Cited by 220
Martin, R. M., Ikeda, K., Cromer, M. K., Uchida, N., Nishimura, T., Romano, R., Tong, A. J., Lemgart, V. T., Camarena, J., Pavel-Dinu, M., et al. (2019) · Cell stem cell · doi:10.1016/j.stem.2019.04.001 · Cited by 206
Self-citationEngineered materials for in vivo delivery of genome-editing machinery
Tong, S., Moyo, B., Lee, C. M., Leong, K. W., & Bao, G. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0145-9 · Cited by 208
Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges
Cavazzana, M., Bushman, F. D., Miccio, A., André‐Schmutz, I., & Six, E. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0020-9 · Cited by 205
Strategies for nonviral nanoparticle‐based delivery of CRISPR/Cas9 therapeutics
Chen, F., Alphonse, M., & Liu, Q. (2020) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1609 · Cited by 197
Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus
Antoniani, C., Meneghini, V., Lattanzi, A., Felix, T., Romano, O., Magrin, E., Weber, L., Pavani, G., El Hoss, S., Kurita, R., et al. (2018) · Blood · doi:10.1182/blood-2017-10-811505 · Cited by 194
Self-citationRecent Advances in the Treatment of Sickle Cell Disease
Cisneros, G. S., & Thein, S. L. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00435 · Cited by 210
Gene correction for SCID-X1 in long-term hematopoietic stem cells
Pavel-Dinu, M., Wiebking, V., Dejene, B. T., Srifa, W., Mantri, S., Nicolas, C. E., Lee, C. M., Bao, G., Kildebeck, E., Punjya, N., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09614-y · Cited by 193
Self-citationEfficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking
Ferrari, S., Jacob, A., Beretta, S., Unali, G., Albano, L., Vavassori, V., Cittaro, D., Lazarević, D., Brombin, C., Cugnata, F., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0551-y · Cited by 188
Rational designs of in vivo CRISPR-Cas delivery systems
Xu, C., Chen, G., Luo, Y., Zhang, Y., Zhao, G., Lu, Z.-D., Czarna, A., Gu, Z., & Wang, J. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.11.005 · Cited by 187
Development of CRISPR-Cas systems for genome editing and beyond
Zhang, F. (2019) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583519000052 · Cited by 188
Piel, F. B., Rees, D. C., DeBaun, M. R., Nnodu, O. E., Ranque, B., Thompson, A. A., Ware, R. E., Abboud, M. R., Abraham, A., Ambrose, E. E., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00096-0 · Cited by 203
Immunogenicity of Cas9 Protein
Mehta, A., & Merkel, O. M. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.10.003 · Cited by 192
Accurate genomic variant detection in single cells with primary template-directed amplification
Gonzalez-Pena, V., Natarajan, S., Xia, Y., Klein, D., Carter, R., Pang, Y., Shaner, B., Annu, K., Putnam, D. K., Chen, W., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2024176118 · Cited by 188
Marker-free coselection for CRISPR-driven genome editing in human cells
Agudelo, D., Duringer, A., Bozoyan, L., Huard, C., Carter, S., Loehr, J., Synodinou, D., Drouin, M., Salsman, J., Dellaire, G., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4265 · Cited by 183
Therapeutic strategies for sickle cell disease: towards a multi-agent approach
Telen, M. J., Malik, P., & Vercellotti, G. M. (2018) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0003-2 · Cited by 188
Ling, S., Yang, S., Hu, X., Yin, D., Dai, Y., Qian, X., Wang, D., Pan, X., Hong, J., Sun, X., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00656-y · Cited by 187
CRISPR–Cas: a tool for cancer research and therapeutics
Yin, H., Xue, W., & Anderson, D. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0166-8 · Cited by 185
Zhang, B. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30064 · Cited by 191
Genome editing of HBG1 and HBG2 to induce fetal hemoglobin
Métais, J.-Y., Doerfler, P. A., Mayuranathan, T., Bauer, D. E., Fowler, S. C., Hsieh, M. M., Katta, V., Keriwala, S., Lazzarotto, C. R., Luk, K., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000820 · Cited by 177
Self-citationBak, R. O., Gomez‐Ospina, N., & Porteus, M. H. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.05.004 · Cited by 181
Self-citationApplications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics
Liu, W., Li, L., Jiang, J., Wu, M., & Lin, P. (2021) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbab014 · Cited by 196
Genome editing via delivery of Cas9 ribonucleoprotein
DeWitt, M. A., Corn, J. E., & Carroll, D. (2017) · Methods · doi:10.1016/j.ymeth.2017.04.003 · Cited by 172
CRISPR-Cas9-mediated homology-directed repair for precise gene editing
Liao, H., Wu, J., VanDusen, N. J., Li, Y., & Zheng, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102344 · Cited by 197
Carlson-Stevermer, J., Abdeen, A. A., Kohlenberg, L., Goedland, M., Molugu, K., Lou, M., & Saha, K. (2017) · Nature Communications · doi:10.1038/s41467-017-01875-9 · Cited by 170
Lattanzi, A., Camarena, J., Lahiri, P., Segal, H., Srifa, W., Vakulskas, C. A., Frock, R. L., Kenrick, J., Lee, C. M., Talbott, N., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf2444 · Cited by 171
Self-citationErythropoiesis: insights into pathophysiology and treatments in 2017
Zivot, A., Lipton, J. M. M., Narla, A., & Blanc, L. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0011-z · Cited by 187
Self-citationReceptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing
Rouet, R., Thuma, B. A., Roy, M. D., Lintner, N. G., Rubitski, D. M., Finley, J. E., Wisniewska, H. M., Mendonsa, R., Hirsh, A., de Oñate, L., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b01551 · Cited by 163
Targeted homology-directed repair in blood stem and progenitor cells with CRISPR nanoformulations
Shahbazi, R., Sghia-Hughes, G., Reid, J. L., Kubek, S., Haworth, K. G., Humbert, O., Kiem, H., & Adair, J. E. (2019) · Nature Materials · doi:10.1038/s41563-019-0385-5 · Cited by 158
Everette, K. A., Newby, G. A., Levine, R. M., Mayberry, K. D., Jang, Y., Mayuranathan, T., Nimmagadda, N., Dempsey, E., Li, Y., Bhoopalan, S. V., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01026-0 · Cited by 169
Balderston, S., Taulbee, J. J., Celaya, E., Fung, K., Jiao, A., Smith, K., Hajian, R., Gasiūnas, G., Kutanovas, S., Kim, D., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00706-z · Cited by 170
Chang, K.-H., Smith, S. E., Sullivan, T., Chen, K., Zhou, Q., West, J. A., Liu, M., Liu, Y., Vieira, B. F., Sun, C., et al. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.009 · Cited by 155
Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges
Luther, D. C., Lee, Y. W., Nagaraj, H., Scaletti, F., & Rotello, V. M. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1517746 · Cited by 162
Han, X., Alu, A., Liu, H., Shi, Y., Wei, X., Cai, L., & Wei, Y. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.01.011 · Cited by 165
Spatial control of in vivo CRISPR–Cas9 genome editing via nanomagnets
Zhu, H., Zhang, L., Tong, S., Lee, C. M., Deshmukh, H., & Bao, G. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0318-7 · Cited by 151
Park, S. H., Lee, C. M., Dever, D. P., Davis, T., Camarena, J., Srifa, W., Zhang, Y., Paikari, A., Chang, A. K., Porteus, M. H., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz475 · Cited by 152
Self-citationLin, J., & Leonard, W. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041447 · Cited by 150
Synthetically modified guide RNA and donor DNA are a versatile platform for CRISPR-Cas9 engineering
Lee, K., Mackley, V. A., Rao, A., Chong, A. T., DeWitt, M. A., Corn, J. E., & Murthy, N. (2017) · eLife · doi:10.7554/elife.25312 · Cited by 147
CRISPR-Cas-mediated transcriptional modulation: The therapeutic promises of CRISPRa and CRISPRi
Bendixen, L., Jensen, T. I., & Bak, R. O. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.03.024 · Cited by 150
Self-citationWeber, L., Frati, G., Felix, T., Hardouin, G., Casini, A., Wollenschlaeger, C., Meneghini, V., Masson, C., De Cian, A., Chalumeau, A., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay9392 · Cited by 140
Site-Specific Gene Editing of Human Hematopoietic Stem Cells for X-Linked Hyper-IgM Syndrome
Kuo, C. Y., Long, J. D., Campo-Fernández, B., Oliveira, S. N. D., Cooper, A. R., Romero, Z. G., Hoban, M. D., Joglekar, A. V., Lill, G. R., Kaufman, M. L., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.103 · Cited by 138
Tregopathies: Monogenic diseases resulting in regulatory T-cell deficiency
Cepika, A., Sato, Y., Liu, J. M.-H., Uyeda, M. J., Bacchetta, R., & Roncarolo, M. G. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.10.026 · Cited by 147
Engineering Protein-Secreting Plasma Cells by Homology-Directed Repair in Primary Human B Cells
Hung, K. L., Meitlis, I., Hale, M. R., Chen, C., Singh, S., Jackson, S. W., Miao, C. H., Khan, I., Rawlings, D. J., & James, R. G. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.012 · Cited by 140
Wimberger, S., Akrap, N., Firth, M. A., Brengdahl, J., Engberg, S., Schwinn, M. K., Slater, M. R., Lundin, A., Hsieh, P.-P., Li, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40344-4 · Cited by 140
Lattanzi, A., Meneghini, V., Pavani, G., Amor, F., Ramadier, S., Félix, T., Antoniani, C., Masson, C., Alibeu, O., Lee, C. M., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.10.008 · Cited by 144
Self-citationVaidyanathan, S., Salahudeen, A. A., Sellers, Z. M., Bravo, D. T., Choi, S. S., Batish, A., Le, W., Baik, R., Sean de la, O., Kaushik, M. P., et al. (2019) · Cell stem cell · doi:10.1016/j.stem.2019.11.002 · Cited by 135
Self-citationFerrari, S., Jacob, A., Cesana, D., Laugel, M., Beretta, S., Varesi, A., Unali, G., Conti, A., Canarutto, D., Albano, L., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.09.001 · Cited by 133
Long-term ex vivo expansion of mouse hematopoietic stem cells
Wilkinson, A. C., Ishida, R., Nakauchi, H., & Yamazaki, S. (2020) · Nature Protocols · doi:10.1038/s41596-019-0263-2 · Cited by 125
Genome editing: A perspective on the application of CRISPR/Cas9 to study human diseases (Review)
Rodríguez-Rodríguez, D. R., Ram�rez‐Sol�s, R., Garza‐Elizondo, M. A., Garza‐Rodr�guez, M., & Barrera-Saldaña, H. A. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4112 · Cited by 145
CRISPR/Cas9 gene-editing: Research technologies, clinical applications and ethical considerations
Memi, F., Ntokou, A., & Papangeli, I. (2018) · Seminars in Perinatology · doi:10.1053/j.semperi.2018.09.003 · Cited by 134
Romero, Z. G., Lomova, A., Said, S., Hoyt-Miggelbrink, A. M., Kuo, C. Y., Campo-Fernández, B., Hoban, M. D., Masiuk, K. E., Clark, D. N., Long, J. D., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.014 · Cited by 123
CRISPR/Cas9: Principle, Applications, and Delivery through Extracellular Vesicles
Horodecka, K., & Düchler, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116072 · Cited by 121
Gene Therapy for β-Hemoglobinopathies
Cavazzana, M., Antoniani, C., & Miccio, A. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.024 · Cited by 132
Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I
Gomez‐Ospina, N., Scharenberg, S. G., Mostrel, N., Bak, R. O., Mantri, S., Quadros, R. M., Gurumurthy, C. B., Lee, C. M., Bao, G., Suarez, C. J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11962-8 · Cited by 124
Self-citationBak, R. O., Dever, D. P., Reinisch, A., Cruz Hernandez, D., Majeti, R., & Porteus, M. H. (2017) · eLife · doi:10.7554/elife.27873 · Cited by 122
Self-citation
Metadata
- Authors
- Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., Uchida, N., Hendel, A., Narla, A., Majeti, R., Weinberg, K. I., & Porteus, M. H.
- Affiliations
- Stanford University (US)
- Institute for Stem Cell Biology and Regenerative Medicine (US)
- Stanford Medicine (US)
- Corresponding author
- Porteus, Matthew H.
- ORCID
- Venue
- Nature
- Published
- 2016-11-07
- Volume
- 539
- Issue
- 7629
- Pages
- 384-389
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5898607
- OpenAlex
- W2547418311
- Semantic Scholar
- 91eb4c33902b14df9b2974a4ce8dc6e3c3a02125
- Cited by
- 864
- References
- 50
- Citations by year
- 2026: 45 · 2025: 75 · 2024: 80 · 2023: 93 · 2022: 76 · 2021: 120 · 2020: 93 · 2019: 90 · 2018: 99 · 2017: 89 · 2016: 4
- FWCI
- 48.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (5r01ai120766-02, R01-AI120766)
- National Eye Institute (PN2EY018244)
- National Institute of General Medical Sciences (T32GM007266)
- National Institute of Allergy and Infectious Diseases (R01-AI120766, R01AI097320)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Keywords
- CRISPR/Cas9 genome editing, beta-globin gene, hematopoietic stem cells, sickle cell disease, beta-thalassemia, homologous recombination, adeno-associated virus vectors, Cas9 ribonucleoprotein, autologous transplantation, reporter genes
- MeSH terms
- Gene Editing, Dependovirus, Alleles, Anemia, Sickle Cell, Animals, Cell Differentiation, Cell Separation, Erythrocytes, Female, Flow Cytometry, Hematopoietic Stem Cells, Humans, Microspheres, Mutation, RNA, Messenger, Genetic Therapy, Mice, SCID, Mice, Inbred NOD, beta-Thalassemia, Genes, Reporter, Gene Targeting, Antigens, CD34, Cell Lineage, beta-Globins, Magnets, Homologous Recombination, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
